(az ith roe mye' sin)
P / L : Caution during pregnancy and lactation
|| See TERMINOLOGY & ABBREVIATIONS ||
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Azithromycin and other antibacterial drugs, Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Azithromycin is indicated for the treatment of MAC infection and prophylaxis against MAC Infection caused by susceptible isolates.
Treatment of Disseminated Mycobacterium avium complex (MAC) Disease
Azithromycin, taken in combination with ethambutol, is indicated for the treatment of disseminated MAC infections in persons with advanced HIV infection.
Prophylaxis of Disseminated Mycobacterium avium complex (MAC) Disease
Azithromycin, taken alone or in combination with rifabutin at its approved dose, is indicated for the prevention of disseminated MAC disease in persons with advanced HIV.
Sexually Transmitted Diseases
Non-gonococcal urethritis and cervicitis due to Chlamydia trachomatis.
Azithromycin, at the recommended dose, should not be relied upon to treat gonorrhea or syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating gonorrhea or syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed.
|Dosage & Administration||
Azithromycin tablets may be taken without regard to food. However, increased tolerability has been observed when tablets are taken with food.
Azithromycin for oral suspension (single dose 1 g packet) can be taken with or without food after constitution. Not for pediatric use. For pediatric suspension, please refer to the INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION sections of the prescribing information for Azithromycin (azithromycin for oral suspension) 100 mg/5 mL and 200 mg/5 mL bottles.
The recommended dose of Azithromycin for the treatment of non-gonococcal urethritis and cervicitis due to C. trachomatis is: a single 1 gram (1000 mg) dose of Azithromycin. This dose can be administered as as one single dose packet (1 g).
Prevention of Disseminated MAC Infections
The recommended dose of Azithromycin for the prevention of disseminated Mycobacterium avium complex (MAC) disease is: 1200 mg taken once weekly. This dose of Azithromycin may be combined with the approved dosage regimen of rifabutin.
Treatment of Disseminated MAC Infections
Azithromycin should be taken at a daily dose of 600 mg, in combination with ethambutol at the recommended daily dose of 15 mg/kg. Other antimycobacterial drugs that have shown in vitro activity against MAC may be added to the regimen of azithromycin plus ethambutol at the discretion of the physician or health care provider.
DIRECTIONS FOR ADMINISTRATION OF Azithromycin for 1 gm oral suspension (when available)
The entire contents of the packet should be mixed thoroughly with two ounces (approximately 60 mL) of water. Drink the entire contents immediately; add an additional two ounces of water, mix, and drink to assure complete consumption of dosage. The single dose packet should not be used to administer doses other than 1000 mg of azithromycin.
Tab & susp: May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Azithromycin is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Azithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin.
Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Stevens Johnson Syndrome and toxic epidermal necrolysis have been reported rarely in patients on azithromycin therapy. Although rare, fatalities have been reported (see CONTRAINDICATIONS). Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurred soon thereafter in some patients without further azithromycin exposure. These patients required prolonged periods of observation and symptomatic treatment. The relationship of these episodes to the long tissue half-life of azithromycin and subsequent prolonged exposure to antigen is unknown at present.
If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.
Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur.
Clostridium Difficile-associated diarrhea
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Azithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen in treatment with macrolides, including azithromycin. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving azithromycin. Providers should consider the risk of QT prolongation which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including:
patients with known prolongation of the QT interval, a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure
patients on drugs known to prolong the QT interval
patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, aminodarone, sotalol) antiarrhythmic agents.Elderly patients may be more susceptible to drug-associated effects on the QT interval.
Because azithromycin is principally eliminated via the liver, caution should be exercised when azithromycin is administered to patients with impaired hepatic function. Due to the limited data in subjects with GFR<10 mL/min, caution should be exercised when prescribing azithromycin in these patients.
Exacerbation of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy.
Prescribing Azithromycin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
|Adverse Drug Reaction(s)||Mild to moderate nausea, vomiting, abdominal pain, dyspepsia, flatulence, diarrhoea, cramping; angioedema, cholestatic jaundice; dizziness, headache, vertigo, somnolence; transient elevations of liver enzyme values.|
Aluminum- and magnesium-containing antacids reduce the peak serum levels (rate) but not the AUC (extent) of azithromycin (500 mg) absorption.
Administration of cimetidine (800 mg) two hours prior to azithromycin had no effect on azithromycin (500 mg) absorption.
A single oral dose of 1200 mg azithromycin did not alter the pharmacokinetics of a single 800 mg oral dose of fluconazole in healthy adult subjects.
Total exposure (AUC) and half-life of azithromycin following the single oral tablet dose of 1200 mg were unchanged and the reduction in Cmax was not significant (mean decrease of 18%) by coadministration with 800 mg fluconazole.
A single oral dose of 1200 mg azithromycin had no significant effect on the pharmacokinetics of indinavir (800 mg indinavir tid for 5 days) in healthy adult subjects.
Coadministration of a single oral dose of 1200 mg azithromycin with steady-state nelfinavir (750 mg tid) to healthy adult subjects produced a decrease of approximately 15% in mean AUC0 8 of nelfinavir and its M8 metabolite. Mean Cmax of nelfinavir and its M8 metabolite were not significantly affected. No dosage adjustment of nelfinavir is required when nelfinavir is coadministered with azithromycin.
Coadministration of nelfinavir (750 mg tid) at steady state with a single oral dose of 1200 mg azithromycin increased the mean AUC0 âˆž of azithromycin by approximately a factor of 2-times (range of up to 4 times) of that when azithromycin was given alone. The mean Cmax of azithromycin was also increased by approximately a factor of 2-times (range of up to 5 times) of that when azithromycin was given alone. Dose adjustment of azithromycin is not recommended. However, when administered in conjunction with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.
Following administration of trimethoprim/sulfamethoxazole DS (160 mg/800 mg) for 7 days to healthy adult subjects, coadministration of 1200 mg azithromycin on the 7th day had no significant effects on peak concentrations (Cmax), total exposure (AUC), and the urinary excretion of either trimethoprim or sulfamethoxazole.
Coadministration of trimethoprim/sulfamethoxazole DS for 7 days had no significant effect on the peak concentration (Cmax) and total exposure (AUC) of azithromycin following administration of the single 1200 mg tablet dose to healthy adult subjects.
Administration of a 600 mg single oral dose of azithromycin had no effect on the pharmacokinetics of efavirenz given at 400 mg doses for 7 days to healthy adult subjects.
Efavirenz, when administered at a dose of 400 mg for seven days produced a 22% increase in the Cmax of azithromycin administered as a 600 mg single oral dose, while the AUC of azithromycin was not affected.
Azithromycin (500 mg Day 1, 250 mg Days 2 5) did not affect the plasma levels or pharmacokinetics of theophylline administered as a single intravenous dose. The effect of azithromycin on the plasma levels or pharmacokinetics of theophylline administered in multiple doses resulting in therapeutic steady-state levels of theophylline is not known. However, concurrent use of macrolides and theophylline has been associated with increases in the serum concentrations of theophylline. Therefore, until further data are available, prudent medical practice dictates careful monitoring of plasma theophylline levels in patients receiving azithromycin and theophylline concomitantly.
Although, in a study of 22 healthy men, a 5-day course of azithromycin did not affect the prothrombin time from a subsequently administered dose of warfarin, spontaneous post-marketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral anticoagulants. Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly.
Dose adjustments are not indicated when azithromycin and zidovudine are coadministered. When zidovudine (100 mg ) was coadministered with daily azithromycin (600 mg, n=5 or 1200 mg, n=7), mean Cmax, AUC and Clr increased by 26% (CV 54%), 10% (CV 26%) and 38% (CV 114%), respectively. The mean AUC of phosphorylated zidovudine increased by 75% (CV 95%), while zidovudine glucuronide Cmax and AUC increased by less than 10%. In another study, addition of 1 gram azithromycin per week to a regimen of 10 mg/kg daily zidovudine resulted in 25% (CV 70%) and 13% (CV 37%) increases in zidovudine Cmax and AUC, respectively. Zidovudine glucuronide mean Cmax and AUC increased by 16% (CV 61%) and 8.0% (CV 32%), respectively.
Doses of 1200 mg/day azithromycin for 14 days in 6 subjects increased Cmax of concurrently administered didanosine (200 mg q.12h) by 44% (54% CV) and AUC by 14% (23% CV). However, none of these changes were significantly different from those produced in a parallel placebo control group of subjects.
Preliminary data suggest that coadministration of azithromycin and rifabutin did not markedly affect the mean serum concentrations of either drug. Administration of 250 mg azithromycin daily for 10 days (500 mg on the first day) produced mean concentrations of azithromycin 1 day after the last dose of 53 ng/mL when coadministered with 300 mg daily rifabutin and 49 mg/mL when coadministered with placebo. Mean concentrations 5 days after the last dose were 23 ng/mL and 21 ng/mL in the two groups of subjects. Administration of 300 mg rifabutin for 10 days produced mean concentrations of rifabutin one half day after the last dose of 60 mg/ml when coadministered with daily 250 mg azithromycin and 71 ng/mL when coadministered with placebo. Mean concentrations 5 days after the last dose were 8.1 ng/mL and 9.2 ng/mL in the two groups of subjects.
The following drug interactions have not been reported in clinical trials with azithromycin; however, no specific drug interaction studies have been performed to evaluate potential drug-drug interaction. Nonetheless, they have been observed with macrolide products. Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised:
Digoxin elevated digoxin levels.
Ergotamine or dihydroergotamine acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
Triazolam decrease the clearance of triazolam and thus may increase the pharmacologic effect of triazolam.
Drugs metabolized by the cytochrome P450 system elevations of serum carbamazepine, cyclosporine, hexobarbital, and phenytoin levels.
Laboratory Test Interactions
There are no reported laboratory test interactions.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no mutagenic potential in standard laboratory tests: mouse lymphoma assay, human lymphocyte clastogenic assay, and mouse bone marrow clastogenic assay.
|Food Interaction||Food may alter absorption.|
|Pregnancy Category (FDA) and use in Specific Population||
Pregnancy Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later trimesters).
It is not known whether azithromycin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when azithromycin is administered to a nursing woman.
In controlled clinical studies, azithromycin has been administered to pediatric patients ranging in age from 6 months to 12 years. For information regarding the use of Azithromycin (azithromycin for oral suspension) in the treatment of pediatric patients, please refer to the INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION sections of the prescribing information for Azithromycin (azithromycin for oral suspension) 100 mg/5 mL and 200 mg/5 mL bottles.
Safety in HIV-Infected Pediatric Patients
Safety and efficacy of azithromycin for the prevention or treatment of MAC in HIV-infected children have not been established. Safety data are available for 72 children 5 months to 18 years of age (mean 7 years) who received azithromycin for treatment of opportunistic infections. The mean duration of therapy was 242 days (range 3 2004 days) at doses of <1 to 52 mg/kg/day (mean 12 mg/kg/day). Adverse events were similar to those observed in the adult population, most of which involved the gastrointestinal tract. Treatment related reversible hearing impairment in children was observed in 4 subjects (5.6%). Two (2.8%) children prematurely discontinued treatment due to side effects: one due to back pain and one due to abdominal pain, hot and cold flushes, dizziness, headache, and numbness. A third child discontinued due to a laboratory abnormality (eosinophilia). The protocols upon which these data are based specified a daily dose of 10 20 mg/kg/day (oral and/or I.V.) of azithromycin.
Pharmacokinetic parameters in older volunteers (65 85 years old) were similar to those in younger volunteers (18 40 years old) for the 5-day therapeutic regimen. Dosage adjustment does not appear to be necessary for older patients with normal renal and hepatic function receiving treatment with this dosage regimen (see CLINICAL PHARMACOLOGY from PI).
In multiple-dose clinical trials of oral azithromycin, 9% of patients were at least 65 years of age (458/4949) and 3% of patients (144/4949) were at least 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Elderly patients may be more susceptible to development of torsades de pointes arrhythmia than younger patients.
Azithromycin 600 mg tablets contain 2.1 mg of sodium per tablet. Azithromycin for oral suspension 1 gram single-dose packets contain 37.0 mg of sodium per packet.
Geriatric Patients with Opportunistic Infections, Including Mycobacterium avium complex (MAC) Disease
Safety data are available for 30 patients (65 94 years old) treated with azithromycin at doses >300 mg/day for a mean of 207 days. These patients were treated for a variety of opportunistic infections, including MAC. The side effect profile was generally similar to that seen in younger patients, except for a higher incidence of side effects relating to the gastrointestinal system and to reversible impairment of hearing.
|Storage||Intravenous: Store below 30Â°C. Oral: Store below 30Â°C.|
Following oral administration, azithromycin is rapidly absorbed and widely distributed throughout the body. Rapid distribution of azithromycin into tissues and high concentration within cells result in significantly higher azithromycin concentrations in tissues than in plasma or serum. The 1 g single dose packet is bioequivalent to four 250 mg azithromycin capsules. The pharmacokinetic parameters of azithromycin in plasma after dosing as per labeled recommendations in healthy young adults and asymptomatic HIV-seropositive adults (age 18 40 years old) are portrayed in the following chart:
Azithromycin blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step.
|ATC Classification||S01AA26 - azithromycin.
J01FA10 - azithromycin; Belongs to the class of macrolides. Used in the treatment of systemic infections.
Search Google: Azithromycin
|Brand Name||Manufacturer/Marketer||Composition||Dosage Form||Pack Size & Price|
|ADIZ||Euro Pharma Ltd.||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|ADIZ Suspension||Euro Pharma Ltd.||Azithromycin 200mg/5ml||Suspension||15ml &30ml: 85.00 & 130.00 MRP|
|AM||Reliance Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||30ml: 85.00 MRP|
|AM 500||Reliance Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||10's: 300.00 MRP|
|APOZITH||Apollo Pharmaceutical Laboratories Ltd.||Azithromycin 500mg||Tablet||12's: 360.00 MRP|
|ASIZITH||Asiatic Laboratories Ltd.||Azithromycin 250mg & 500mg||Tablet||6's each: 120.00 & 180.00 MRP|
|ASIZITH Suspension||Asiatic Laboratories Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|ATM||Everest Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|ATM 500||Everest Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||6's: 180.00 MRP|
|AVALON||Techno Drugs||Azithromycin USP 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|AVALON 500||Techno Drugs||Azithromycin USP 500mg||Tablet||6's: 180.00 MRP|
|AVALON I/V||Techno Drugs||Azithromycin USP 500mg/5ml (I/V)||Injection||500mg vial: 240.00 MRP|
|AZ||Aristopharma Ltd.||Azithromycin 200mg/5ml||Suspension||20ml, 35ml, 50ml: 100.00 & 140.00 & 200.00 MRP|
|AZ Ophthalmic||Aristopharma Ltd.||Azithromycin 1% eye drop||Solution||2.5ml: 120.00 MRP|
|AZ-250||Aristopharma Ltd.||Azithromycin 250mg||Capsule||10's: 200.00 MRP|
|AZ-500||Aristopharma Ltd.||Azithromycin 500mg||Capsule||9's: 270.00 MRP|
|AZALID||Orion Pharma Ltd.||Azithromycin 250mg & 500mg||Capsule||250mg x6's, 500mg x8's: 120.48 & 240.88 MRP|
|AZALID Suspension||Orion Pharma Ltd.||Azithromycin 200mg/5ml||Suspension||35ml, 50ml: 130.00 & 160.00 MRP|
|AZALTIC||NIPRO JMI Pharma Ltd.||Azithromycin USP 500mg||Tablet||6's: 180.00 MRP|
|AZALTIC Suspension||NIPRO JMI Pharma Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 35ml: 85.00 & 130.00 MRP|
|AZASITE||Sharif Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|AZASITE Suspension||Sharif Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||20ml, 35ml: 85.00 & 130.00 MRP|
|AZEBAC||S.N. Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||12's: 361.32 MRP|
|AZEXIA||Pharmasia Limited||Azithromycin 500mg||Tablet||3's & 6's: 90.33 & 180.66 MRP|
|AZEXIA Suspension||Pharmasia Limited||Azithromycin 200mg/5ml||Suspension||20ml, 35ml: 80.31 & 130.00 MRP|
|AZI-S||Seema Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||15ml: 100.00 MRP|
|AZI-S 500||Seema Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||6's: 160.00 MRP|
|AZICIN||Opsonin Pharma Limited||Azithromycin 250mg & 500mg||Tablet||6's each: 120.00 & 180.00 MRP|
|AZICIN Capsule||Opsonin Pharma Limited||Azithromycin 250mg||Capsule||6's: 120.00 MRP|
|AZICIN Suspension||Opsonin Pharma Limited||Azithromycin 200mg/5ml||Suspension||20ml, 35ml, 50ml: 85.00 & 130.00 & 185.00 MRP|
|AZILIT||Desh Pharmaceuticals (Pvt) Ltd||Azithromycin 200mg/5ml||Suspension||15ml: 85.00 MRP|
|AZILIT-500||Desh Pharmaceuticals (Pvt) Ltd||Azithromycin 500mg||Tablet||3's: 90.00 MRP|
|AZIMET||Medimet Pharmaceuticals Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|AZIMET-500||Medimet Pharmaceuticals Ltd||Azithromycin 500mg||Tablet||4's: 120.00 MRP|
|AZIMEX||Drug International Ltd||Azithromycin 250mg & 500mg||Tablet||250mg x20's, 500mg x9's: 400.00 & 270.00 MRP|
|AZIMEX Suspension||Drug International Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 90.00 & 130.00 MRP|
|AZIMON||Monico Pharma Limited||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 90.00 & 130.00 MRP|
|AZIMON 500||Monico Pharma Limited||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|AZIN||The Acme Laboratories Ltd.||Azithromycin 500mg||Tablet||3's & 6's: 90.33 & 180.66 MRP|
|AZIN Capsule||The Acme Laboratories Ltd.||Azithromycin 250mg||Capsule||6's: 120.42 MRP|
|AZIN Suspension||The Acme Laboratories Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.32 & 130.49 MRP|
|AZINIL||Apex Pharmaceuticals Ltd.||Azithromycin 250mg & 500mg||Tablet||6's each: 120.00 & 180.00 MRP|
|AZINIL Suspension||Apex Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||20ml, 35ml: 80.00 & 130.00 MRP|
|AZIREX||Belsen Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||6's: 180.00 MRP|
|AZIROX||Navana Pharmaceuticals Limited||Azithromycin 500mg||Tablet||9's: 270.99 MRP|
|AZIROX Suspension||Navana Pharmaceuticals Limited||Azithromycin 200mg/5ml||Suspension||20ml, 35ml: 85.00 & 130.00 MRP|
|AZITEL||Cosmic Chemical Industries Limited||Azithromycin 200mg/5ml||Suspension||15ml, 35ml: 85.00 & 130.00 MRP|
|AZITEL-500||Cosmic Chemical Industries Limited||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|AZITHIN||Chemist Laboratories Ltd.||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|AZITHIN Suspension||Chemist Laboratories Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 35ml: 85.00 & 130.00 MRP|
|AZITHROCIN 30ML||Beximco Pharmaceuticals Ltd||Azithromycin monohydrate usp eq. to azithromycin 200mg/5ml||Suspension||30ml: 130.00 MRP|
|AZITHROCIN 500||Beximco Pharmaceuticals Ltd||Azithromycin Monohydrate USP equivalent to Azithromycin 500mg||Tablet||9's: 315.00 MRP|
|AZITHROCIN 500 CAPSULE||Beximco Pharmaceuticals Ltd||Azithromycin USP 500mg||Capsule||10's: 250.00 MRP|
|AZITHROCIN 500 IV||Beximco Pharmaceuticals Ltd||Inj. Azithromycin 500mg (I/V)||Injection||1's: 460.00 MRP|
|AZITHROCIN POWDER||Beximco Pharmaceuticals Ltd||Azithromycin 200mg/5ml||Powder for Suspension||50ml: 185.00 MRP|
|AZITHROCIN SUSP||Beximco Pharmaceuticals Ltd||Azithromycin monohydrate usp eq. to azithromycin 200mg/5ml||Suspension||15ml: 85.00 MRP|
|AZITHROMAX||Ziska Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 35ml: 85.00 & 130.00 MRP|
|AZITHROMAX 500||Ziska Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||5's: 150.00 MRP|
|AZITOR 500||Central Pharmaceuticals Ltd||Azithromycin 500mg||Tablet||5's: 150.00 MRP|
|AZITRA 500||Syntho Laboratories Ltd.||Azithromycin 500mg||Tablet||3's: 75.00 MRP|
|AZIX||Amico Laboratories Ltd.||Azithromycin 500mg||Tablet||6's: 180.00 MRP|
|AZIX Suspension||Amico Laboratories Ltd.||Azithromycin 200mg/5ml||Suspension||15ml: 85.00 MRP|
|AZMIN||Modern Pharmaceuticals Ltd||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|AZO||Delta Pharma Limited||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|AZO 500||Delta Pharma Limited||Azithromycin 500mg||Tablet||9's: 270.00 MRP|
|AZOMAC||General Pharmaceuticals Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 35ml: 85.32 & 130.49 MRP|
|AZOMAC 500||General Pharmaceuticals Ltd||Azithromycin 500mg||Tablet||6's: 180.66 MRP|
|AZRO||Nipa Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||12's: 360.00 MRP|
|AZYTH 250||Sandoz/Novartis||Azithromycin Dihydrate USP 524.03mg equivalent to Azithromycin 500mg||Tablet||6's: MRP 303.42|
|AZYTH 500||Sandoz/Novartis||Azithromycin Dihydrate USP 262.015mg equivalent to Azithromycin 250mg||Tablet||10's: MRP 300.00|
|AZYTH SUSPENSION||Sandoz/Novartis||Azithromycin monohydrate USP 200mg/5ml Powder for Suspension||Suspension||15ml: 100.00, 30ml: 140.00 MRP|
|BENZITH||Benham Pharmaceuticals Ltd||Azithromycin USP 500mg||Tablet||8's: 240.00 MRP|
|BENZITH Suspension||Benham Pharmaceuticals Ltd||Azithromycin USP 200mg/5ml||Suspension||15ml: 90.00 MRP|
|BP-Z||Bristol Pharma Limited||Azithromycin 500mg||Tablet||6's: 180.00 MRP|
|BP-Z Capsule||Bristol Pharma Limited||Azithromycin 500mg||Capsule||3's: 90.00 MRP|
|BP-Z Suspension||Bristol Pharma Limited||Azithromycin 200mg/5ml||Suspension||15ml: 85.00 MRP|
|CINALID||Jayson Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||3's: 75.30 IP|
|CINALID Suspension||Jayson Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||15ml: 75.28 IP|
|CURAZITH||Sanofi||Azithromycin 250mg & 500mg||Tablet||250mg x6's, 500mg x12's: 120.00 & 360.00 MRP|
|CURAZITH Suspension||Sanofi||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|DEMACRO||Decent Pharma Laboratories Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|DEMACRO-500||Decent Pharma Laboratories Ltd.||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|EZITH||Edruc Limited||Azithromycin 500mg||Tablet||3's: 90.00 IP|
|EZITH Suspension||Edruc Limited||Azithromycin 200mg/5ml||Suspension||15ml: 85.00 IP|
|FIZYTH||Peoples Pharma Ltd.||Azithromycin 500mg||Tablet||500mg x8's, 500mg x12's: 176.00 & 280.00 MRP|
|HYZITH||Millat Pharmaceuticals Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|HYZITH-500||Millat Pharmaceuticals Ltd||Azithromycin 500mg||Tablet||3's & 6's: 90.00 & 180.00 MRP|
|ILOZIN||Doctors Chemical Works Ltd||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|ILOZIN Suspension||Doctors Chemical Works Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|INDOZITH||Indo-Bangla Pharmaceuticals Works Ltd.||Azithromycin 500mg||Tablet||6's: 180.00 MRP|
|INDOZITH Capsule||Indo-Bangla Pharmaceuticals Works Ltd.||Azithromycin 250mg||Capsule||6's: 180.00 MRP|
|INDOZITH Suspension||Indo-Bangla Pharmaceuticals Works Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 25ml: 85.00 & 120.00 MRP|
|MACAZI||Pacific Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||3's & 6's: 89.40 & 178.80 MRP|
|MACAZI Suspension||Pacific Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 35ml: 64.00 & 118.00 MRP|
|MACROBAC||Concord Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||6's: 180.00 MRP|
|MACROBAC Suspension||Concord Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||25ml, 35ml: 120.00 & 135.00 MRP|
|MACROZITH||Silva Pharmaceuticals Limited||Azithromycin 500mg||Tablet||6's: 180.68 MRP|
|MACROZITH Capsule||Silva Pharmaceuticals Limited||Azithromycin 250mg||Capsule||6's: 120.44 MRP|
|MACROZITH Suspension||Silva Pharmaceuticals Limited||Azithromycin 200mg/5ml||Suspension||15ml, 25ml: 85.32 & 115.43 MRP|
|MACZITH||Biopharma Laboratories Ltd||Azithromycin 500mg||Tablet||12's: 361.32 MRP|
|MACZITH Capsule||Biopharma Laboratories Ltd||Azithromycin 250mg||Capsule||6's: 120.48 MRP|
|MACZITH Suspension||Biopharma Laboratories Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 35ml: 85.32 & 130.49 MRP|
|MAZITH||Hallmark Pharmaceuticals Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 25ml: 85.32 & 110.42 MRP|
|MAZITH 500||Hallmark Pharmaceuticals Ltd||Azithromycin 500mg||Tablet||5's & 12's: 140.00 & 336.00 MRP|
|N-ZITH||Novus Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||15ml: 85.00 MRP|
|N-ZITH-500||Novus Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||6's: 180.00 MRP|
|NEOZITH||Marksman Pharmaceuticals Ltd||Azithromycin 200mg/5ml||Suspension||15ml: 85.00 MRP|
|NEOZITH 500||Marksman Pharmaceuticals Ltd||Azithromycin 500mg||Tablet||3's: 90.00 MRP|
|ODAZ||Unimed & Unihealth Manufacturers Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|ODAZ-500||Unimed & Unihealth Manufacturers Ltd.||Azithromycin 500mg||Tablet||6's: 180.00 MRP|
|ODAZYTH||ACI Ltd.||Azithromycin 500mg||Tablet||12's: 361.32 MRP|
|ODAZYTH Drop||ACI Ltd.||Azithromycin 1% eye drop||Eye Drop||2.5ml: 110.41 IP|
|ODAZYTH Suspension||ACI Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 30ml, 50ml: 85.32, 130.49 & 185.70 MRP|
|PENALOX||Rephco Laboratories Ltd.||Azithromycin 500mg||Tablet||6's: 180.00 MRP|
|PENALOX Suspension||Rephco Laboratories Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 95.00 & 130.00 MRP|
|PHAGOCIN||Shamsul Alamin Pharmaceuticals Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 35ml: 85.00 & 130.00 MRP|
|PHAGOCIN-500||Shamsul Alamin Pharmaceuticals Ltd||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|RANZITH||Rangs Pharmaceuticals Ltd.||Azithromycin 250mg & 500mg||Capsule||6's each: 120.00 & 180.00 MRP|
|RANZITH Suspension||Rangs Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|RAZITHRO||R A K Pharmaceuticals Pvt. Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 35ml: 85.00 & 130.00 MRP|
|RAZITHRO 500||R A K Pharmaceuticals Pvt. Ltd.||Azithromycin 500mg||Tablet||6's: 180.00 MRP|
|RESPAZIT||Somatec Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||3's & 6's: 84.30 & 168.60 MRP|
|RESPAZIT Capsule||Somatec Pharmaceuticals Ltd.||Azithromycin 250mg||Capsule||6's: 120.48 MRP|
|RESPAZIT Suspension||Somatec Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 20ml, 30ml: 80.30, 85.32 & 130.49 MRP|
|ROMYCIN||IBN SINA Pharmaceutical Industry Ltd.||Azithromycin 500mg||Tablet||12's: 420.00 IP|
|ROMYCIN 250||IBN SINA Pharmaceutical Industry Ltd.||Azithromycin 250mg||Capsule||8's: 160.00 MRP|
|ROMYCIN Drop||IBN SINA Pharmaceutical Industry Ltd.||Azithromycin 1% eye drop||Eye Drop||2.5ml: 115.00 IP|
|ROMYCIN Suspension||IBN SINA Pharmaceutical Industry Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 20ml, 35ml, 50ml: 90.00, 100.00, 135.00, 190.00 IP|
|ROZITH 15ml||Healthcare Pharmacuticals Ltd.||Azithromycin 200mg/5ml powder for Suspension||Suspension||15ml, MRP 95 Tk|
|ROZITH 22.5ml||Healthcare Pharmacuticals Ltd.||Azithromycin 200mg/5ml powder for Suspension||Suspension||22.5ml, MRP 105 Tk|
|ROZITH 250||Healthcare Pharmacuticals Ltd.||Azithromycin USP 250mg||Tablet||6's MRP 150 Tk|
|ROZITH 35ml||Healthcare Pharmacuticals Ltd.||Azithromycin 200mg/5ml powder for Suspension||Suspension||35ml, MRP 140 Tk|
|ROZITH 500||Healthcare Pharmacuticals Ltd.||Azithromycin USP 500mg||Tablet||12's MRP 420 Tk|
|ROZITH 50ml||Healthcare Pharmacuticals Ltd.||Azithromycin 200mg/5ml powder for Suspension||Suspension||50ml, MRP 185 Tk|
|ROZITH 60ml||Healthcare Pharmacuticals Ltd.||Azithromycin 200mg/5ml powder for Suspension||Suspension||60ml, MRP 250 Tk|
|ROZITH Injection||Healthcare Pharmacuticals Ltd.||Azithromycin 500 mg Injection||Injection||1's: 460.00 MRP|
|SIMPLI-3||Beacon Pharmaceuticals Limited||Azithromycin 500mg||Tablet||8's: 280.88 MRP|
|SIMPLI-3 Suspension||Beacon Pharmaceuticals Limited||Azithromycin 200mg/5ml||Suspension||20ml, 35ml: 85.00 & 130.49 MRP|
|SIMPLI-4||Beacon Pharmaceuticals Limited||Azithromycin 500mg/5ml||Injection||500mg vial: 460.00 MRP|
|SOTO||Hudson Pharmaceuticals Ltd||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|SOTO Suspension||Hudson Pharmaceuticals Ltd||Azithromycin 200mg/5ml||Suspension||15ml: 85.00 MRP|
|THIZA||Kumudini Pharma Ltd||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|THIZA Suspension||Kumudini Pharma Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|THROMAX||Novo Healthcare and Pharma Ltd.||Azithromycin 250mg & 500mg||Tablet||6's each: 120.00 & 180.00 MRP|
|THROMAX Suspension||Novo Healthcare and Pharma Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 25ml, 35ml: 90.00, 110.00 & 130.00 MRP|
|Tridosil 15ml||Incepta Pharmaceuticals Limited||Azithromycin 200 mg/5 ml Powder For Suspension||Suspension||15ml:MRP 85 Tk|
|Tridosil 250||Incepta Pharmaceuticals Limited||Azithromycin Dihydrate USP 262.015 mg equivalent to Azithromycin 250 mg||Tablet||6's:MRP 120 Tk|
|Tridosil 30ml||Incepta Pharmaceuticals Limited||Azithromycin 200 mg/5 ml Powder For Suspension||Suspension||30ml:MRP 130 Tk|
|Tridosil 35ml||Incepta Pharmaceuticals Limited||Azithromycin 200 mg/5 ml Powder For Suspension||Suspension||35ml:MRP 140 Tk|
|Tridosil 500||Incepta Pharmaceuticals Limited||Azithromycin Dihydrate USP 524.03 mg equivalent to Azithromycin 500 mg||Tablet||6's:MRP 180 Tk|
|Tridosil 500 12's||Incepta Pharmaceuticals Limited||Azithromycin Dihydrate USP 524.03 mg equivalent to Azithromycin 500 mg||Tablet||12's:MRP 360 Tk|
|Tridosil 50ml||Incepta Pharmaceuticals Limited||Azithromycin 200 mg/5 ml Powder For Suspension||Suspension||50ml:MRP 185 Tk|
|Tridosil IV||Incepta Pharmaceuticals Limited||Azithromycin 500 mg Injection||Infusion||1x1's:MRP 460 Tk|
|TRUZITH||The White Horse Pharma||Azithromycin USP 500mg||Tablet||8's: 240.00 MRP|
|XOLIDE||Radiant Pharmaceuticals Ltd.||Azithromycin 250mg & 500mg||Capsule||6's each: 162.00 & 240.00 MRP|
|XOLIDE Suspension||Radiant Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||30ml: 145.00 MRP|
|ZEMYCIN||Gaco Pharmaceutical Ltd.||Azithromycin 500mg||Tablet||3's: 90.00 MRP|
|ZEMYCIN Suspension||Gaco Pharmaceutical Ltd.||Azithromycin 200mg/5ml||Suspension||15ml: 85.00 MRP|
|ZENICIN||Zenith Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 50ml: 82.00 & 200.00 MRP|
|ZENICIN 500||Zenith Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||6's: 168.00 MRP|
|ZEOCIN-500||APC Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||3's: 90.00 MRP|
|ZIBAC||Popular Pharmaceuticals Ltd.||Azithromycin 250mg & 500mg||Tablet||250mg x8's, 500mg x18's: 160.64 & 541.98 MRP|
|ZIBAC Drop||Popular Pharmaceuticals Ltd.||Azithromycin 1% eye drop||Eye Drop||2.5ml: 110.41 MRP|
|ZIBAC I/V||Popular Pharmaceuticals Ltd.||Azithromycin USP 500mg/5ml (I/V)||Injection||500mg vial: 461.74 MRP|
|ZIBAC Suspension||Popular Pharmaceuticals Ltd.||Azithromycin 200mg/5ml||Suspension||15ml, 20ml, 25ml, 35ml, 50ml: 85.32, 100.00, 115.01, 130.49 & 185.70 MRP|
|ZIMAX 250||Square Pharmaceuticals Ltd.||Azithromycin 250mg||Capsule||2x6's: 300.96|
|ZIMAX 250 TAB||Square Pharmaceuticals Ltd.||Azithromycin 250mg||Tablet||1x10's: 250.80|
|ZIMAX 500||Square Pharmaceuticals Ltd.||Azithromycin 500mg||Tablet||2x6's: 421.32|
|ZIMAX 500 IV||Square Pharmaceuticals Ltd.||Azithromycin 500mg/vial||IV Infusion||1x1's: 461.38|
|ZIMAX PFS 15||Square Pharmaceuticals Ltd.||Azithromycin 200mg/5 ml||Powder for Suspension||15 ml: 85.58|
|ZIMAX PFS 30||Square Pharmaceuticals Ltd.||Azithromycin 200mg/5 ml||Powder for Suspension||30 ml: 130.88|
|ZIMAX PFS 50||Square Pharmaceuticals Ltd.||Azithromycin 200mg/5 ml||Powder for Suspension||50 ml: 186.25|
|ZINEX||Alco Pharma Ltd||Azithromycin 250mg & 500mg||Tablet||250mg x6's, 500mg x8's: 120.00 & 240.00 MRP|
|ZINEX Suspension||Alco Pharma Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 80.00 & 130.00 MRP|
|ZITA||Kemiko Pharmaceuticals Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 85.00 & 130.00 MRP|
|ZITA-500||Kemiko Pharmaceuticals Ltd||Azithromycin 250mg & 500mg||Tablet||250mg x3's, 500mg x6's: 90.00 & 180.00 MRP|
|ZITHRIN||Renata Limited||Azithromycin 250mg & 500mg||Tablet||12's each: 216.84 & 216.84 MRP|
|ZITHRIN Capsule||Renata Limited||Azithromycin 250mg||Capsule||12's: 240.84 MRP|
|ZITHRIN I/V||Renata Limited||Azithromycin USP 500mg/5ml (I/V)||Injection||500mg vial: 460.00 MRP|
|ZITHRIN Suspension||Renata Limited||Azithromycin 200mg/5ml||Suspension||15ml, 20ml, 35ml, 50ml: 80.30, 85.32, 130.00 & 185.00 MRP|
|ZITHRO||Pharmadesh Laboratories Limited||Azithromycin 250mg & 500mg||Capsule||6's each: 120.36 & 180.66 MRP|
|ZITHRO Suspension||Pharmadesh Laboratories Limited||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 86.11 & 125.47 MRP|
|ZITHROLEX||Mystic Pharmaceuticals Limited||Azithromycin 250mg & 500mg||Tablet||250mg x6's, 500mg x3's: 114.00 & 84.00 MRP|
|ZITHROLEX Suspension||Mystic Pharmaceuticals Limited||Azithromycin 200mg/5ml||Suspension||15ml: 84.00 MRP|
|ZITHROX||Eskayef Bangladesh Ltd||Azithromycin 250mg & 500mg||Tablet||250mg x6's & 500mg x12's MRP: 120.00 & 363.96|
|ZITHROX Suspension||Eskayef Bangladesh Ltd||Azithromycin 200mg/5ml||Suspension||20ml, 35ml, 50ml MRP: 85.00,130.00, 180.00|
|ZITREX||Medicon Laboratories Ltd||Azithromycin 200mg/5ml||Suspension||20ml, 35ml: 85.00 & 130.00 MRP|
|ZITREX 500||Medicon Laboratories Ltd||Azithromycin 500mg||Tablet||8's: 240.00 MRP|
|ZYCIN||Globe Pharmaceuticals Ltd||Azithromycin 200mg/5ml||Suspension||15ml, 30ml: 80.00 & 120.00 MRP|
|ZYCIN-500||Globe Pharmaceuticals Ltd||Azithromycin 500mg||Tablet||6's: 180.00 MRP|
[Posted 03/12/2013. Raised in the USA]
ISSUE: FDA is warning the public that azithromycin (US brand, Azithromycin or Zmax) can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm. Patients at particular risk for developing this condition include those with known risk factors such as existing QT interval prolongation, low blood levels of potassium or magnesium, a slower than normal heart rate, or use of certain drugs used to treat abnormal heart rhythms, or arrhythmias. FDA has issued a Drug Safety Communication today as a result of our review of a study by medical researchers as well as another study by a manufacturer of the drug that assessed the potential for azithromycin to cause abnormal changes in the electrical activity of the heart.
FDA previously released a Statement on May 17, 2012, about a study that compared the risks of cardiovascular death in patients treated with the antibacterial drugs azithromycin, amoxicillin, ciprofloxacin, and levofloxacin, or no antibacterial drug. The study reported an increase in cardiovascular deaths, and in the risk of death from any cause, in persons treated with a 5-day course of azithromycin compared to persons treated with amoxicillin, ciprofloxacin, or no drug. The risks of cardiovascular death associated with levofloxacin treatment were similar to those associated with azithromycin treatment.
BACKGROUND: Azithromycin is marketed in the USA, under the brand names Azithromycin and Zmax. FDA-approved indications for azithromycin include: acute bacterial exacerbations of chronic obstructive pulmonary disease, acute bacterial sinusitis, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections, urethritis and cervicitis, genital ulcer disease.
RECOMMENDATION: Health care professionals should consider the risk of torsades de pointes and fatal heart rhythms with azithromycin when considering treatment options for patients who are already at risk for cardiovascular events. FDA notes that the potential risk of QT prolongation with azithromycin should be placed in appropriate context when choosing an antibacterial drug: Alternative drugs in the macrolide class, or non-macrolides such as the fluoroquinolones, also have the potential for QT prolongation or other significant side effects that should be considered when choosing an antibacterial drug. For more information visit the FDA website at: http://www.fda.gov/Safety/MedWatch/SafetyInformation and http://www.fda.gov/Drugs/DrugSafety.
Why is Azithromycin prescribed?
Azithromycin is used to treat certain bacterial infections, such as bronchitis; pneumonia; sexually transmitted diseases (STD); and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs. Azithromycin is in a class of medications called macrolide antibiotics. It works by stopping the growth of bacteria. Antibiotics will not kill viruses that can cause colds, flu, or other infections.
How should Azithromycin be used?
Azithromycin comes as a tablet, capsule, suspension to take by mouth, and injection or solution as well. The tablets and suspension are usually taken with or without food once a day upto 5 days or as directed by your doctor. The extended-release suspension is usually taken on an empty stomach (at least 1 hour before or 2 hours after a meal) as a one-time dose. To help you remember to take azithromycin, take it around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take azithromycin exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Shake the liquid well before each use to mix the medication evenly. Use a dosing spoon, oral syringe, or measuring cup to measure the correct amount of medication. Rinse the measuring device with water after taking the full dose of medication.
If you receive azithromycin extended-release suspension as a dry powder you must first add water to the bottle before you take the medication. Open the bottle by pressing down on the cap and twisting. Measure 1/4 cup (60 mL) of water and add to the bottle. Close the bottle tightly and shake well to mix.
Use the extended-release liquid within 12 hours of receiving it from the pharmacy or adding water to the powder.
If you vomit within an hour after taking azithromycin, call your doctor right away. Your doctor will tell you if you need to take another dose. Do not take another dose unless your doctor tells you to do so.
You should begin to feel better during the first few days of treatment with azithromycin. If your symptoms do not improve, or get worse, call your doctor.
Take azithromycin until you finish the prescription, even if you feel better. If you stop taking azithromycin too soon or skip doses, your infection may not be completely treated and the bacteria may become resistant to antibiotics.
Other uses for Azithromycin
Azithromycin is also used sometimes to treat H. pylori infection, traveler's diarrhea, and other gastrointestinal infections; Legionnaires' disease (a type of lung infection); disseminated Mycobacterium avium complex (MAC) infection [a type of lung infection that often affects people with human immunodeficiency virus (HIV)]; pertussis (whooping cough; a serious infection that can cause severe coughing); and babesiosis (an infectious disease carried by ticks). It is also used to prevent heart infection in people having dental or other procedures, and to prevent STD in victims of sexual assault. Talk to your doctor about the possible risks of using Azithromycin for your condition.
Azithromycin may be prescribed for other uses; ask your doctor for more information.
What special precautions to follow?
Before taking azithromycin,
- tell your doctor if you are allergic to azithromycin, clarithromycin, dirithromycin, erythromycin, telithromycin or any other medications.
- tell your doctor what other prescription and nonprescription medication you are taking.
|| See FDA approved Prescribing Information from Brand Manufacturer |||Manufacturer's|
|| Back to top ||
*Trademark name & prescribing information are the property of their respective Manufacturers.